Logo image of NOV.DE

NOVO NORDISK A/S-B (NOV.DE) Stock Price, Quote, News and Overview

FRA:NOV - Deutsche Boerse Ag - DK0062498333 - Common Stock - Currency: EUR

82.3  +2.3 (+2.88%)

NOV.DE Quote, Performance and Key Statistics

NOVO NORDISK A/S-B

FRA:NOV (2/5/2025, 12:40:04 PM)

82.3

+2.3 (+2.88%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High138.48
52 Week Low71.62
Market Cap365.43B
Shares4.44B
Float4.38B
Yearly Dividend7.54
Dividend Yield1.64%
PE28.98
Fwd PE22.07
Earnings (Next)02-05 2025-02-05/bmo
IPO05-17 1974-05-17


NOV.DE short term performance overview.The bars show the price performance of NOV.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

NOV.DE long term performance overview.The bars show the price performance of NOV.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of NOV.DE is 82.3 EUR. In the past month the price decreased by -1.12%. In the past year, price decreased by -28.35%.

NOVO NORDISK A/S-B / NOV Daily stock chart

NOV.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY.DE ELI LILLY & CO 81.81 764.20B
1LLY.MI ELI LILLY & CO 79.43 741.99B
ZEG.DE ASTRAZENECA PLC 18.22 413.69B
JNJ.DE JOHNSON & JOHNSON 15.25 355.12B
1JNJ.MI JOHNSON & JOHNSON 15.23 354.69B
1SAN.MI SANOFI 14.78 260.95B
SAN.PA SANOFI 14.61 257.86B
SNW.DE SANOFI 14.58 257.34B
1MRKX.MI MERCK & CO. INC. 16.39 238.80B
6MK.DE MERCK & CO. INC. 15.1 220.08B
1PFE.MI PFIZER INC 10.24 145.02B
PFE.DE PFIZER INC 10 141.65B

Related stock screener links

About NOV.DE

Company Profile

NOV logo image Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO NORDISK A/S-B

Novo Alle 1

Bagsvaerd DK

Employees: 71880

Company Website: https://www.novonordisk.com/

Investor Relations: https://www.novonordisk.com/investors.html

Phone: 4544448888

NOV.DE FAQ

What is the stock price of NOV.DE?

The current stock price of NOV.DE is 82.3 EUR.


What is the symbol for NOVO NORDISK A/S-B stock?

The exchange symbol of NOVO NORDISK A/S-B is NOV and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is NOV.DE stock listed?

NOV.DE stock is listed on the Deutsche Boerse Ag exchange.


Is NOV.DE a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NOV.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NOV.DE.


Does NOV.DE stock pay dividends?

NOV.DE has a dividend yield of 1.64%. The yearly dividend amount is currently 7.54.


When does NOV.DE stock report earnings?

NOV.DE will report earnings on 2025-02-05, before the market open.


What is the Price/Earnings (PE) ratio of NOV.DE?

The PE ratio for NOV.DE is 28.98. This is based on the reported non-GAAP earnings per share of 2.84 and the current share price of 82.3 EUR.


NOV.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NOV.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NOV.DE. NOV.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NOV.DE Financial Highlights

Over the last trailing twelve months NOV.DE reported a non-GAAP Earnings per Share(EPS) of 2.84. The EPS decreased by 26.83% compared to the year before.


Industry RankSector Rank
PM (TTM) 35.01%
ROA 23.83%
ROE 78.59%
Debt/Equity 0.43
Chartmill High Growth Momentum
EPS Q2Q%22.4%
Sales Q2Q%21.42%
EPS 1Y (TTM)26.83%
Revenue 1Y (TTM)26.15%

NOV.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to NOV.DE. The Buy consensus is the average rating of analysts ratings from 30 analysts.

For the next year, analysts expect an EPS growth of 21.91% and a revenue growth 24.84% for NOV.DE


Ownership
Inst Owners37.53%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts74
Price Target118.83 (44.39%)
EPS Next Y21.91%
Revenue Next Year24.84%